Univariable modelOR (95% CI) (n = 757–776) | Baseline model*OR (95% CI) (n = 748) | Longitudinal model⁋OR (95% CI) (n = 748) | |
---|---|---|---|
Baseline variable | |||
Age, 10 years | 0.81 (0.72–0.91) | 0.83 (0.72–0.95) | 0.83 (0.73–0.94) |
Female sex | 0.80 (0.56–1.13) | ‡ | ‡ |
Disease duration, 10 years | 0.69 (0.55–0.85) | 0.89 (0.67–1.17) | 0.89 (0.68–1.17) |
Obesity (BMI ≥ 25) | 0.88 (0.64–1.20) | ‡ | ‡ |
Ever-smokers | 0.89 (0.67–1.19) | ‡ | ‡ |
Positive HLA-B27 (vs. negative) | 1.69 (1.04–2.74) | 1.50 (0.83–2.71) | 1.47 (0.84–2.56) |
AS (vs. nr-axSpA) | 0.77 (0.48–1.21) | ‡ | ‡ |
TNFi naïve | 1.75 (1.26–2.43) | 1.49 (1.01–2.20) | 1.44 (0.98–2.10) |
Baseline BASDAI, unit | 1.64 (1.52–1.78) | 1.61 (1.48–1.75) | 1.93 (1.72–2.16) |
Baseline CRP, mg/dL | 1.21 (1.10–1.33) | 1.13 (1.04–1.23) | 1.13 (1.04–1.22) |
Longitudinal variable | |||
Follow-up time (vs. interval in the 1-year follow-up) | Reference | † | Reference |
Interval in the 2-year follow-up | 0.99 (0.81–1.20) | † | 0.52 (0.35–0.77) |
Interval in the 3-year follow-up | 0.60 (0.46–0.79) | † | 0.27 (0.16–0.45) |
BASDAIt − 1, unit | 1.12 (1.08–1.15) | † | 0.78 (0.70–0.89) |
CRPt − 1, mg/dL | 1.11 (1.04–1.18) | † | 1.01 (0.94–1.08) |
Concomitant NSAID use during the interval | 0.80 (0.60–1.07) | † | ‡ |
Concomitant sulfasalazine use during the interval | 0.69 (0.32–1.47) | † | ‡ |
Concomitant MTX use during the interval | 1.04 (0.49–2.24) | † | ‡ |
Group according to the interval DQ | |||
Control group (DQ = 100) | Reference | Reference | Reference |
Mild-tapering group (50 ≤ DQ < 100) | 0.93 (0.73–1.20) | 0.94 (0.70–1.26) | 1.03 (0.61–1.74) |
Heavy-tapering group (DQ < 50) | 0.80 (0.43–1.51) | 0.82 (0.34–1.97) | 1.09 (0.26–4.55) |
QIC of the model | 1367.597 | 1317.502 |